TRIP
GnRH agonist used medically for advanced prostate cancer and central precocious puberty. With continued use it causes initial GnRH receptor stimulation followed by pituitary downregulation (suppression). A single low dose has been promoted informally for restarting the hypothalamic-pituitary-gonadal axis after androgen use; no published clinical study supports this.
Regulatory status (as of Sept 2026)
Approved prescription GnRH agonist for prostate cancer and central precocious puberty. Use as a single-dose 'HPTA restart' is off-label, unstudied and not a recognised indication. Not addressed by the April 2026 503A Category 2 removals or the July 2026 PCAC votes.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote1 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Triptorelin is an FDA-approved prescription drug. GnRH agonist used medically for advanced prostate cancer and central precocious puberty.
| Half-life | Geometric mean terminal half-life 2.8 h in healthy males after a 0.5 mg IV bolus detailsGeometric mean terminal half-life 2.8 h in healthy males after a 0.5 mg IV bolus; 6.6-7.7 h in males with renal or hepatic impairment (three-compartment model) |
|---|---|
| How it's given in studies | Intramuscular injection |
| Research stage | FDA-approved |
| Dosing | Published research: 0.5 mg IV bolus in the human PK study details0.5 mg IV bolus in the human PK study; approved clinical use is sustained-release intramuscular depot injection (e.g. monthly and 3-monthly formulations) for prostate cancer and central precocious puberty. No published study supports a 100 mcg single dose for restarting the HPG axis.Community-reportedCommunity-reported: 100 mcg (single dose for HPTA), intramuscular injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It first stimulates, then shuts down, the brain signal that drives sex hormones when used continuously. Initial GnRH receptor stimulation followed by downregulation with continued use.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedUsers have reported 100 mcg (single dose for HPTA) — intramuscular injection. This is not a recommendation.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Triptorelin | Geometric mean terminal half-life 2.8 h in healthy males after a 0.5 mg IV bolus; 6.6-7.7 h in males with renal or hepatic impairment (three-compartment model) | Intramuscular injection | FDA-approved |
| Gonadorelin | No published PK data found | Subcutaneous injection | Discontinued |
| Kisspeptin-10 | Kisspeptin-10: ~4 min (mice, IV/systemic); ~28 min (27.6 ± 1.1) is kisspeptin-54 in human males (IV infusion) | Subcutaneous or IV injection | Phase 1 / early human |
| PT-141 (Bremelanotide) | No published PK data found | Subcutaneous injection | FDA-approved |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Sexual Health category. View All Sexual Health Peptides
Metabolic
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.